As of November 6, 2026, Enveric Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 29, 2026 (Form 8-K, May 29, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Enveric Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Enveric Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-29. Every row below is cited to the filing it comes from, and this page adds each new change as Enveric Biosciences, Inc. files it.
Also on the record for Enveric Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13G, by Sio Capital Management, LLC | 7.37% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by EASTON JEFF | 1.4% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Ayrton Capital LLC | 2.93% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by EASTON JEFF | 7.87% of the class | 5%+ stakes | Source |
| May 4, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| February 11, 2026 | Form D, private offering | $1.45M sold | Form D page | Source |
| February 4, 2026 | Stake report, Schedule 13G, by Lind Global Fund III LP | 9.99% of the class | 5%+ stakes | Source |
| February 2, 2026 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| January 5, 2026 | Stake report, Schedule 13G/A, by AdvisorShares Trust | 1.66% of the class | 5%+ stakes | Source |
| December 23, 2025 | Form D, private offering | $107K sold | Form D page | Source |
| December 17, 2025 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Enveric Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Enveric Biosciences, Inc. and the records around it.
Enveric Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing May 2026
- Form D filing May 2026
- Form D filing Feb 2026
- Who owns it
Companies that share a holder
- Northstrive Fund II LP also filed stake reports on 2 other companies: Bluejay Diagnostics, Inc. (Jun 2026), enVVeno Medical Corp (Feb 2026)
- Braeden Lichti also filed stake reports on 3 other companies: enVVeno Medical Corp (Sep 2026), PMGC Holdings Inc. (Jun 2026), Bluejay Diagnostics, Inc. (Jun 2026)
- AdvisorShares Trust also filed stake reports on 8 other companies: Neuphoria Therapeutics Inc. (Oct 2026), PSYENCE BIOMEDICAL LTD. (Oct 2026), Silo Pharma, Inc. (Jul 2026)
Watch Enveric Biosciences, Inc.
Get an email when Enveric Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Enveric Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Enveric Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enveric Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-29 | Reported | not named in the filing | 8-K, 2026-05-29 |
New leaders reset buying decisions — get the Full Report on Enveric Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Enveric Biosciences, Inc. (free up to 3)
Find people with the same kind of experience as the senior executive at Enveric Biosciences, Inc., with the record behind each one.
Find candidates like senior executive at Enveric Biosciences, Inc.Every change, in the filing's words
Reported
The RSA Agreement generally provides for time-based vesting on a specified vesting date, subject to continued service through such date, with unvested shares forfeited upon a termination of service prior to vesting, and includes customary restrictions on transfer and provisions regarding stockholder rights prior to vesting.
- On May 22, 2026, the Compensation Committee recommended, and the Board of Directors (the "Board") of Enveric Biosciences, Inc. (the "Company") approved and adopted, (i) a new form of Restricted Stock Unit Award Agreement ("RSU Agreement") and (ii) a new form of Restricted Stock Award Agreement (the "RSA Agreement", and together with the RSU Agreement, the "Award Agreements"), in each case under the Company's 2020 Long-Term Incentive Plan, as amended (the "Plan").
- The RSU Agreement provides for time-based vesting over a four-year period, with 25% of the award vesting on the first anniversary of the grant date and the remaining portion vesting in substantially equal monthly installments thereafter, and generally provides that vested units are settled upon a change in control or termination of service, subject to compliance with Section 409A of the Internal Revenue Code.
- The RSU Agreement also includes provisions providing for full vesting upon a change in control, limited accelerated vesting upon certain qualifying terminations, forfeiture of unvested units upon termination of service, and, in the case of a termination for cause, forfeiture of vested but unsettled units.
- The Award Agreements will be used in connection with future grants of restricted stock units and restricted stock to the Company's named executive officers and directors, as applicable.
Enveric Biosciences, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Enveric Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.